BioRestorative Therapies (BRTX) Q2 2024 Earnings

BRTX·Reported August 13, 2024·After market close

BioRestorative Therapies reported Q2 2024 revenue of $89.1K, beat analyst consensus of $10.0K by $79.1K. Diluted EPS came in at $-0.50, beat the $-0.56 consensus by $0.06.

Revenue

$89.1Kbeat by $79.1K

Consensus: $10.0K

Diluted EPS

$-0.50beat by $0.06

Consensus: $-0.56

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0001493152-24-031636

Financial Snapshot

Trailing eight quarters through Q2 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q2 2024 Earnings FAQ

Common questions about BioRestorative Therapies's Q2 2024 earnings report.

BioRestorative Therapies (BRTX) reported Q2 2024 earnings on August 13, 2024 after market close.

BioRestorative Therapies reported revenue of $89.1K and diluted EPS of $-0.50 for Q2 2024.

Revenue beat the consensus estimate of $10.0K by $79.1K. EPS beat the consensus estimate of $-0.56 by $0.06.

You can read the 10-Q periodic report (0001493152-24-031636) directly on SEC EDGAR. The filing index links above go to sec.gov.